Post by PharmaShots

16,936 followers

šš¢š„š„š¢šØš§-ššØš„š„ššš« ššžššš„š¬. šš«šžššš¤š­š”š«šØš®š š” šœš„š¢š§š¢šœššš„ šššš­šš. š‹ššš§šš¦ššš«š¤ š«šžš š®š„ššš­šØš«š² ššžšœš¢š¬š¢šØš§š¬. This week's PharmaShots Weekly captures the biggest stories shaping the global biopharma landscape. Inside this edition: šŸ’° Major Deals & M&A ā€¢ AlzeCure Pharma partnered with #QuantumCell in a licensing deal worth up to $2.2B for its Alzheimer's candidate ACD856. ā€¢ CSPC Pharmaceutical Group and AstraZeneca signed a ~$1.77B collaboration to develop next-generation siRNA therapies. ā€¢ Ipsen announced the acquisition of Kartos Therapeutics, Inc. Therapeutics for up to ~$1.75B and Memo Therapeutics for over ā‚¬700M, strengthening its oncology and transplant pipeline. ā€¢ Zymeworks Inc. acquired Theravance Biopharma US, LLC Biopharma (~$929M), while United Therapeutics Corporation acquired Thymmune Therapeutics (~$300M). šŸ§¬ Clinical Milestones ā€¢ Sanofi's Nexviazyme achieved positive Phase III results in infantile-onset Pompe disease. ā€¢ AbbVie & Genmab's Epcoritamab significantly improved progression-free survival in DLBCL. ā€¢ Roche's Divarasib outperformed current KRAS G12C inhibitors in Phase III NSCLC. ā€¢ Samsung Bioepis reported positive biosimilar data for SB27 (Keytruda biosimilar). šŸ† Regulatory & MedTech Highlights ā€¢ FDA approval for Viridian Therapeutics, Inc.'s Lumvoa and Orca Bio's Tregzi. ā€¢ European Commission approval expanded Daiichi Sankyo Japan & AstraZeneca's Enhertu pan-tumor indication. ā€¢ Novocure, Median Technologies, and RefleXion Medical advanced next-generation oncology technologies through key regulatory milestones. From blockbuster transactions and pipeline expansion to clinical breakthroughs and regulatory momentum, this edition delivers the insights every biopharma professional should know. šŸ“© Stay ahead of the industry. Subscribe to PharmaShots Weekly and never miss the stories shaping the future of healthcare. šŸ‘‰ Subscribe Now: https://lnkd.in/gTU62Zbz #PharmaShots #WeeklyNewsletter #Biopharma #Pharma #Healthcare #Biotech #ClinicalTrials #DrugDevelopment #MergersAndAcquisitions #Licensing #RegulatoryAffairs #MedTech #Oncology #LifeSciences #HealthcareInnovation

Post content